On November 9, Amgen gave the latest signal of its intention to market a biosimilar to AbbVie’s Humira (adalimumab) by presenting detailed findings from a head-to-head phase III clinical study. The study, presented orally at the 2015 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting in San Francisco, compared the safety, efficacy and immunogenicity of Humira to that of Amgen’s ABP 501 biosimilar candidate in patients with moderate-to-severe rheumatoid arthritis.
